Spots Global Cancer Trial Database for Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

Official Title: A Phase II Trial of Bevacizumab Plus Gemcitabine™ and Oxaliplatin™ as First Line Therapy in Metastatic or Locally Advanced (Unresectable) Pancreatic Cancer

Study ID: NCT00222469

Conditions

Metastatic Pancreatic Cancer

Interventions

bevacizumab

gemcitabine

oxaliplatin

Study Description

Brief Summary: The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival. In addition, the study will find out what side effects patients may have by taking bevacizumab, oxaliplatin, and gemcitabine together.

Detailed Description: Design: * A phase II single arm study. All patients receive bevacizumab 10mg/kg and gemcitabine 1000mg/m2 on day 1 followed by oxaliplatin 100mg/m2 on day 2 of a 14 day cycle. Purpose: * The purpose of this study is to find out if giving patients bevacizumab, along with the chemotherapy drugs oxaliplatin and gemcitabine, will improve overall survival. In addition, the study will find out what side effects patients may have by taking bevacizumab, oxaliplatin and gemcitabine together. Enrollment: * Approximately 30 patients will be enrolled to the study between the University of Oklahoma and M.D. Anderson Cancer Center. Duration: * The study will be conducted over approximately 2 years.